Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene therapy AB-1005 delivered to the putamen in patients with multiple system atrophy ...
Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 "Completion of the SAD portion with a favorable safety and tolerability ...
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS) (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback